Pre-made Tebotelimab biosimilar ( Bispecific scFv with Crossover, anti-PDCD1;LAG3 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-556
Anti-PDCD1;LAG3 therapeutic antibody (Pre-made Tebotelimab biosimilar,Bispecific scFv with Crossover) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tebotelimab (MGD013) is a bispecific monoclonal antibody. It is anticipated that MGD013 could be used for the treatment of a wide range of cancers, including both solid tumors and hematological malignancies.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-PDCD1;LAG3 therapeutic antibody (Pre-made Tebotelimab biosimilar,Bispecific scFv with Crossover)|
|Format||Bispecific scFv with Crossover|
|Highest_Clin_Trial (Jan '20)||Phase-II/III|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Active||Gastic cancer;Oesophageal cancer;Head and neck cancer;Cholangiocarcinoma;Liver cancer;Haematological malignancies;Malignant melanoma;Solid tumours|